论文部分内容阅读
目的评价艾迪联合吉西他滨与顺铂化疗方案(GP)治疗晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法收治晚期NSCLC患者69例,单用GP化疗为对照组(36例):吉西他滨1000 mg·m-2,iv,d 1,8;顺铂30 mg·m-2,iv,d 2~4;GP联合艾迪化疗方案作为试验组(33例),在GP方案基础上,加艾迪50mL,iv,qd,10 d,均化疗4个周期,评价2组患者化疗临床疗效及不良反应。结果试验组客观有效率(30.3%)明显高于对照组(12.1%)(P<0.05);试验组胃肠道反应及血液学毒性等化疗相关不良反应明显低于对照组(P<0.05)。结论艾迪联合GP化疗方案治疗晚期NSCLC可以显著提高临床疗效,降低不良反应。
Objective To evaluate the clinical efficacy and safety of Aidi combined with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Sixty-nine patients with advanced NSCLC were enrolled in this study. Patients in the chemotherapy group were treated with GP alone (36 cases): gemcitabine (1000 mg · m -2, iv, d 1,8); cisplatin 30 mg · m -2, iv, d 2 ~ ; GP combined with Aidi chemotherapy as the experimental group (33 cases), on the basis of the GP regimen, plus Eddie 50mL, iv, qd, 10d, all chemotherapy 4 cycles, evaluation of two groups of patients with clinical efficacy and adverse reactions. Results The objective effective rate (30.3%) in the experimental group was significantly higher than that in the control group (12.1%) (P <0.05). The adverse reactions such as gastrointestinal reaction and hematological toxicity in the experimental group were significantly lower than those in the control group (P <0.05) . Conclusion Aidi combined with GP chemotherapy in the treatment of advanced NSCLC can significantly improve the clinical efficacy and reduce adverse reactions.